Skip to main content
. 2023 Mar 27;2023(3):CD009885. doi: 10.1002/14651858.CD009885.pub3

5.7. Analysis.

5.7

Comparison 5: Serious adverse events: parallel‐group trials and first‐period cross‐over trials, Outcome 7: Skeletal and muscular system (including pain)